8-K 1 v438425_8k.htm FORM 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):

May 2, 2016

 

 

 

LIPOCINE INC.

 

(Exact name of registrant as specified in its charter)

 

Commission File No. 001-36357

 

Delaware   99-0370688
(State or other jurisdiction of
incorporation)		   (IRS Employer
Identification Number)

 

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code: (801) 994-7383

 

Former name or former address, if changed since last report: Not Applicable

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 7.01Regulation FD Disclosures

 

On May 2, 2016, Lipocine Inc. issued a press release announcing the presentation of TLANDO™ (“LPCN 1021”) clinical data at the 2016 American Urological Association Meeting in San Diego, CA. The press release is filed as Exhibit 99.1 and is incorporated herein by reference. Additionally, the Company submitted two abstracts containing TLANDO clinical data at the 2016 American Urological Association Meeting in San Diego, CA and one abstract at the American Association for Clinical Endocrinologists Annual Meeting in Orlando, FL. The Company’s abstracts are filed as Exhibit 99.2, Exhibit 99.3 and Exhibit 99.4 and are incorporated herein by reference.

 

Item 9.01Financial Statements and Exhibits.

 

(d)Exhibits

 

The following exhibits are filed with this report:

 

Exhibit No.   Description
     
99.1   Press Release Announcing the Presentation of TLANDO Clinical Data at the 2016 American Urological Association Meeting
     
99.2   Abstract Concerning Long-term Safety and Tolerability of Oral Testosterone (LPCN 1021) in Hypogonadal Men: Results from the 52-Week Phase 3 Study
     
99.3   Abstract Concerning Hypogonadal Men with Sexual Function Disorder Benefit from LPCN 1021 (Oral Testosterone) – SOAR (Study of Androgen Replacement) Trial
     
99.4   Abstract Concerning Hypogonadal Men with Diabetes Benefit from LPCN 1021 (Oral Testosterone)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      LIPOCINE INC.
         
Date: May 2, 2016   By: /s/ Mahesh V. Patel
        Mahesh V. Patel
        President and Chief Executive Officer